USFDAApr 27, 2026, 08:49 AM
ADIL Submits AD04 for FDA Priority Voucher Pilot Program
AI Summary
Adial Pharmaceuticals submitted its AD04 product application for the FDA Commissioner's National Priority Voucher Pilot Program (CNPV). This program, announced in 2025, aims to accelerate FDA review for drugs addressing national health priorities, potentially reducing review timelines from 10-12 months to 1-2 months. The company believes this strategic move could significantly expedite AD04's potential approval and market availability for Alcohol Use Disorder patients.
Key Highlights
- ADIL submitted AD04 application for FDA Commissioner's National Priority Voucher Pilot Program.
- CNPV program aims to speed up FDA review for drugs addressing 5 key U.S. national health priorities.
- Potential review timeline of 1-2 months, compared to standard 10-12 months.
- Vouchers are non-transferable and non-sellable.
- AD04 is a genetically targeted therapeutic for Alcohol Use Disorder (AUD).
- Company plans a new Phase 3 clinical trial program for AD04.
- AD04 also has potential for Opioid Use Disorder, gambling, and obesity.
Price Impact
More from ADIL